News | January 04, 2022
Domestic and emerging markets will drive pharma growth: ICRA
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
The current annual U.S. market for prazosin hydrochloride 1mg, 2mg, 5mg strengths is approximately US $ 54 million, according to IQVIA/IMS Health
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The company will market it under the brand name Molflu
Subscribe To Our Newsletter & Stay Updated
